COMP <GO>
UFPT vs XRAY // ENTERPRISE SCALE & MARKET CAP
UFP Technologies Inc. (NASDAQ) VS. DENTSPLY SIRONA Inc. (NASDAQ) • 15-METRIC TALLY: UFPT 7
— XRAY 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UFPT
LAST: $283.97 (-0.19%) • MKT CAP: $2.20B
market-cap
$2.20B
LAST: $9.90 (+3.88%) • MKT CAP: $1.90B
market-cap
$1.90B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UFPT VS. XRAY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UFPT | XRAY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.30% | 50.00% | -21.70 | XRAY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.90% | -11.00% | +24.90 | UFPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.05% | 12.27% | -8.22 | XRAY | /fcf-yield <GO> |
| Operating Margin | 15.30% | -11.50% | +26.80 | UFPT | /operating-margins <GO> |
| Net Profit Margin | 11.30% | -16.20% | +27.50 | UFPT | /net-margins <GO> |
| Revenue Growth (YoY) | 19.50% | -3.00% | +22.50 | UFPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 6.68% | -6.68 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.31 | 0.45 | +7.86 | UFPT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 6/9 | +3.00 | UFPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.0 | 54.6 | -9.60 | XRAY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.20B | $1.90B | $303.8M | UFPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UFPT REV | XRAY REV | UFPT GROSS % | XRAY GROSS % | UFPT FCF | XRAY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $602.8M | $3.68B | 28.3% | 50.0% | $91.9M | $235.0M |
| FY 2024 | $504.4M | $3.79B | 29.1% | 51.6% | $56.9M | $461.0M |
| FY 2023 | $400.1M | $3.96B | — | — | $41.3M | $377.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UFPT // BETA —
XRAY // BETA —